Actively Recruiting
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
Led by N.N. Alexandrov National Cancer Centre · Updated on 2026-03-16
120
Participants Needed
1
Research Sites
417 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a randomized trial evaluating the results of using of PD-1 and PD-L1 immune checkpoint inhibitors combined with chemotherapy, with or without bevacizumab, in patients with metastatic, persistent, and recurrent cervical cancer.
CONDITIONS
Official Title
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 75 years
- Histologically confirmed diagnosis of cervical cancer
- Diagnosis of metastatic cervical cancer (stage IVB according to FIGO 2018)
- Diagnosis of persistent cervical cancer after radical treatment for stages IIB-IVA (FIGO 2018)
- Diagnosis of recurrent cervical cancer after completed radical treatment for stages IA-IVB (FIGO 2018)
- Availability of material for determining PD-L1 expression for immunotherapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- No contraindications to chemotherapy, immunotherapy, or bevacizumab
- Signed informed consent to participate in the study
You will not qualify if you...
- Presence of another active malignant invasive neoplasm
- Pregnancy or lactation period
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
N.N. Alexandrov National Caner Centre
Minsk, Lesnoy, Belarus, 223040
Actively Recruiting
Research Team
Y
Yana Kamko
CONTACT
S
Sergey Mavrichev
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here